

ANNUAL REPORT

LIFEHOUSE GYNAECOLOGICAL ONCOLOGY GROUP

2014

Prepared by
Professor Jonathan Carter

MBBS, DipRACOG, FACS, FRANZCOG, MS, MD, CGO
Professor Gynaecological Oncology, The University of Sydney
Head, Lifehouse Gynaecological Oncology Group



THE UNIVERSITY OF
SYDNEY



Chris O'Brien
Lifehouse

Table of Contents

Introduction	4
Highlights	5
Summary Statistics.....	6
2014 Quality Performance Indicator Numbers	6
Patient Activity 2008-2014	7
Surgical Load	8
Length of Stay	8
Quality Performance Indicator Incidence for Malignant Patients 2014	10
Cumulative Quality Performance Indicator Incidence for Malignant Patients 2009-2014.....	11
Adverse Events 2014	12
Meeting Attendance	13
Publications	14
International Presentations	15
National Presentations	15
Local Presentations.....	17
Abstracts	17
Invited Lectureship, Guest or Program Chair	18
Grants and Awards (+/-Submitted)	19
Research Supervision.....	19
Ethics Approved Studies	20
Grant, Trial, Thesis & Manuscript Reviews	21
Appointments	23
Administrative Responsibilities.....	23
Course Organisation	23
Committee Membership.....	24
Selection Committees	24
Media & Fund Raising.....	25
College Activities; Lectures	25
University Activities	25
Courses/Conferences Attended.....	27
Trials List.....	29

Introduction



It has been quite a momentous year, having completed our first year in The Chris O'Brien Lifehouse. We are delighted with the new premises, with our new approach to care and have received nothing but compliments from our patients.

Our Group currently comprises 4 surgeons, Prof Jonathan Carter, Clin A/Prof Selvan Path, Clin A/Prof Sam Saidi and Clin A/Prof Trevor Tejada-Berges. Our senior nurses include Shannon Philp our Nurse Practitioner and Jayne Manalang our

Clinical Nurse Consultant. Our clinical Fellows are Dr Unine Herbst and Dr Tony Richards. Dr Stephen Cotterell is our Data Manager and Database programmer and Christine Young remains our ever faithful Patient Navigator. Our newest team member is Gel Bolanos our registered nurse in Clinical Trials.

Our extended Multidisciplinary Team include Dr Lyndal Anderson (Pathology), Dr Wendy Brown, Dr Sam McCormack and Dr YuXuan Kitzing (Radiology), A/Prof Philip Beale and Dr Michelle Harrison (Medical Oncology), A/Prof Chris Milross, Clin Assoc Prof Kerwyn Foo, Dr Joanne Toohey (Radiation Oncology), Camron Ebzeny and Annabelle Ng (Genetics).

Overall we continue to excel, not only in patient care, but in teaching, education, research and administration. We have been able to maintain and improve upon our standards and achievements from previous years, with the expectation that this will continue into 2015 and beyond.

My plans for the future include the development of a tertiary ovarian cancer surgical unit and to assist Lifehouse in developing a robotic surgical program.

Highlights

- Shannon Philp and A/Prof Tejada-Berges have initiated and developed Australia's first, Nurse Practitioner Led GTD Clinic at Lifehouse
- Dr Tejada-Berges received academic promotion to Clinical Associate Professor
- Dr Unine Herbst joined our Group as Clinical Fellow
- Dr Richards successfully passed the oral and written CGO examination
- A/Prof Pather was elected to the Human Research Ethics Committee
- Dr Anderson was invited for the National Representative for National Coalition of Public Pathology for "Consultation session on the renewal of the National Cervical Screening Program. Department Health, Australian Government Canberra. 25th November 2014
- Dr Anderson and co-investigators including Prof Carter received Sydney Local Health District Cancer Services Research Grant for the study of Next Generation Sequencing of HPV driven cervical carcinomas.
- Our Group successfully presented our 10th Annual Advances in Gynaecological Oncology Symposium


Summary Statistics

	Prof Carter	A/Prof Pather	A/Prof Saidi	A/Prof Tejada-Berges
Inpatients				
Malignant	63	84	47	50
Benign	134	109	59	97
Consults	9	8	4	3
Total Inpatients	206	201	110	150
Outpatients	1538	2081	1260	1239
Total Inpatient/Outpatient	1744	2282	1370	1389
New cancers	43	72	38	54

2014 Quality Performance Indicator Numbers

	Prof Carter	A/Prof Pather	A/Prof Saidi	A/Prof Tejada-Berges
Admission to ICU		2		1
Anastomotic Leak				
Bladder Injury	1	1		
Bowel Injury	1	1	1	1
Death from Treatment Complications				
Death within 30 days of surgery				
DVT or PE				1
Febrile Morbidity	2	1		1
Hospital Readmission	6	3	5	2
Laparoscopy converted to laparotomy	1		1	1
LOS more than 7 days	2	7	2	9
Nerve Injury	1			
Nosocomial Infection	1			
Perioperative Cardiac Event				
Perioperative Respiratory Event				1
Post-operative Renal Impairment	1			4
Return to OT	1	1		2
Transfusion Intra Op		1	3	2
Transfusion Post Op	1	3		1
Transfusion Pre Op				
Treatment Refusal				
Undiagnosed Cancer		1		
Ureteric Injury				
Vascular Injury				
Wound Dehiscence			1	1
Superficial Diathermy Burn				
Inadvertent Diathermy Bowel				

Patient Activity 2008-2014




Surgical Load

Surgical Load	Prof Carter	A/Prof Pather	A/Prof Saidi	A/Prof Tejada-Berges
Laparotomy	42	19	15	31
Laparoscopy	7	45	44	28
Vulva	8	12	1	3
Conversions	1	0	1	1
Surgical Other	2	11	3	10
Non Surgical	11	10	10	7

Length of Stay

LOS	Prof Carter	A/Prof Pather	A/Prof Saidi	A/Prof Tejada-Berges
Overall Average LOS	3.17	2.76	2.12	3.66
Overall Median LOS	2.5	2	2	2
Laparotomy	3	3	3	3
Laparoscopy	1	1	1	1
Vulva	2.5	2.5	1	1
Surgical Other	2	3	2	2.5
Non Surgical	3	2.5	2	4

Note: Figures apply to surgery on patients with malignancy who were admitted to the ward (TPU patients not included here).



Quality Performance Indicator Incidence for Malignant Patients 2014

Expressed as a percentage of malignant surgeries performed

	Prof Carter	A/Prof Pather	A/Prof Saidi	A/Prof Tejada-Berges
Admission to ICU		0.8%		0.4%
Anastomotic Leak				
Bladder Injury	0.4%	0.4%		
Bowel Injury	0.4%	0.4%	0.4%	0.4%
Death from Treatment Complications				
Death within 30 days of surgery				
DVT or PE				0.4%
Febrile Morbidity	0.8%	0.4%		0.4%
Hospital Readmission	2.5%	1.3%	2.1%	0.8%
Laparoscopy converted to laparotomy	0.4%		0.4%	0.4%
LOS more than 7 days	0.8%	2.9%	0.8%	3.8%
Nerve Injury	0.4%			
Nosocomial Infection	0.4%			
Perioperative Cardiac Event				
Perioperative Respiratory Event				0.4%
Post-operative Renal Impairment	0.4%			1.7%
Return to OT	0.4%	0.4%		0.8%
Transfusion Intra Op		0.4%	1.3%	0.8%
Transfusion Post Op	0.4%	1.3%		0.4%
Transfusion Pre Op				
Treatment Refusal				
Undiagnosed Cancer		0.4%		
Ureteric Injury				
Vascular Injury				
Wound Dehiscence			0.4%	0.4%
Superficial Diathermy Burn				
Inadvertent Diathermy Bowel				

Cumulative Quality Performance Indicator Incidence for Malignant Patients 2009-2014

	Prof Carter	Dr Dalrymple	A/Prof Pather	A/Prof Saidi	A/Prof Tejada-Berges
Admission to ICU	9	1	5	1	1
Anastomotic Leak					
Bladder Injury	2		2		
Bowel Injury	4		4	1	1
Death from Treatment Complications					
Death within 30 days of surgery	2				
DVT or PE	7	1			1
Febrile Morbidity	2		1		1
Hospital Readmission	27	3	22	7	2
Laparoscopy converted to laparotomy	4	3	15	1	1
LOS more than 7 days	40	17	72	2	9
Nerve Injury	2				
Nosocomial Infection	7	1	4		
Perioperative Cardiac Event	4	3	1		
Perioperative Respiratory Event	2				1
Post-operative Renal Impairment	2		1		4
Return to OT	9	1	6	2	2
Transfusion Intra Op	4		7	6	1
Transfusion Post Op	6		4		1
Transfusion Pre Op	2				
Treatment Refusal					
Undiagnosed Cancer			1		
Ureteric Injury					
Vascular Injury					
Wound Dehiscence		2		1	1
Superficial Diathermy Burn	1		1		
Inadvertent Diathermy Bowel					

Adverse Events 2014

	Prof Carter	A/Prof Pather	A/Prof Saidi	A/Prof Tejada-Berges
Acute kidney injury (Grade 1)				2
Acute kidney injury (Grade 2)				2
Acute kidney injury (Grade 3)	1			
Anaemia (Grade 2)		1		1
Anaemia (Grade 3)				3
Ankle fracture (Grade 1)	1			
Atrial flutter (Grade 2)				1
Cervicitis infection (Grade 3)			1	
Constipation (Grade 2)	1			
Creatinine increased (Grade 2)	1			
Fever (Grade 1)	1			
Hematoma (Grade 1)	2			
Hypocalcaemia (Grade 1)	1			
Hypokalaemia (Grade 2)	1			
Hypokalaemia (Grade 3)				1
Hypomagnesaemia (Grade 1)	1		1	1
Hypotension (Grade 2)	1			
Hypotension (Grade 3)			1	
Ileus (Grade 2)				1
Ileus (Grade 3)				1
Infusion related reaction (Grade 2)				
Intra-abdominal haemorrhage (Grade 3)		1		
Intraop gastrointestinal injury (Grade 1)	1	1		1
Intraop gastrointestinal injury (Grade 2)			1	
Intraoperative haemorrhage (Grade 1)	1			
Intraoperative haemorrhage (Grade 2)			1	
Intraoperative urinary injury (Grade 1)	1	1		
Ischemia cerebrovascular (Grade 1)	1			
Lung infection (Grade 3)				1
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify (Grade 3)				1
Pelvic infection (Grade 2)			1	
Pelvic infection (Grade 3)	1			
Peripheral motor neuropathy (Grade 2)	1			
Pleural effusion (Grade 2)				1
Postoperative haemorrhage (Grade 1)			1	
Postoperative haemorrhage (Grade 2)	1		1	
Postoperative haemorrhage (Grade 3)		1		
Respiratory, thoracic and mediastinal disorders - Other, specify (Grade 2)				1
Small intestinal obstruction (Grade 3)	1			
Small intestinal obstruction (Grade 4)				1
Surgical and medical procedures - Other, specify (Grade 3)				1

Urinary retention (Grade 2)	1		1	1
Urinary tract infection (Grade 2)	1			
Urinary tract infection (Grade 3)				1
Urine output decreased (Grade 3)		1		
Uterine haemorrhage (Grade 2)	1			
Uterine perforation (Grade 2)			1	
Vaginal infection (Grade 2)			1	
Wound infection (Grade 1)				1
Wound infection (Grade 2)	2	1		2
Wound infection (Grade 3)	1	1		

Meeting Attendance

	Prof Carter	A/Prof Pather	A/Prof Saidi	A/Prof Tejada- Berges
Attendance Tumour Board	37	34	41	41
Attendance Area M&M	8	6	10	11

Publications

1. Ahmadi N, Tan KK, Solomon MJ, Al-Mozany N, **Carter J**. Pelvic exenteration for primary and recurrent gynecologic malignancies is safe and achieves acceptable long-term outcomes. *J Gynecol Surg* 2014;30(5):255-259
2. **Carter J, Philp S**, O'Connell R. A 5-Year review of gynaecological oncology patients managed by a fast track surgery program. *IJCM* 2014; 5: 36-41
3. Marriquon-Harris, Rhou J, Storey D, **Pather S** Prolonged survival after laparoscopic splenectomy for recurrent ovarian cancer and no adjuvant therapy: a report and review of the literature. *South Afr J Gynaecol Oncol* 2013;5(2):58-61
4. **Philp S, Carter J, Pather S**, Barnett C, D'Abrew N, White K (2014) Patients' satisfaction with Fast Track Surgery in Gynaecological Oncology. *European Journal of Cancer Care*, DOI 10.1111/ecc.12254
5. **Richards A, Dalrymple C** (2014). Abnormal cervicovaginal cytology, unsatisfactory colposcopy and the use of vaginal estrogen cream: An observational study of clinical outcomes for women in low estrogen states. *J Obstet Gynaecol Res*. 2014 Nov 5. doi: 10.1111/jog.12545.
6. **Pather S**, Strockyj S, **Richards A**, Campbell N, De Vries B, Ogle R. Maternal outcome after conservative management of placenta percreta at caesarean section: A report of three cases and a review of the literature. *Australian and New Zealand Journal of Obstetrics and Gynaecology* 2014; 54(1): 84-87.
7. **Pather S**, Strockyj S, **Richards A**, Campbell N, De Vries B, Ogle R (2014). Re: ANZJOG-2013-0458 - Placenta percreta: Multidisciplinary team may not be enough. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 54(3), 292-292
8. Robison K, Clark L, Eng W, Wu L, Raker C, Clark M, **Tejada-Berges T**, Dizon DS. Cervical cancer prevention: Asian-American women's knowledge and participation in screening practices. *Women's Health Issues*. 2014 Mar-Apr;24(2):e231-6.
9. Smith SK, Petrak LM, Dhillon HM, Taylor J, **Milross CG**. Are radiation oncologists aware of health literacy among people with cancer treated with radiotherapy? *Eur J Cancer Care (Engl)*. 2014 Jan;23(1):111-20. doi: 10.1111/ecc.12111. Epub 2013 Aug 19.
10. Sundaresan P, **Milross CG**, Smith A, Evans A, Stockler MR, King MT. Factors influencing the use of RT in NSW: a qualitative study exploring consumer and health professional perspectives. *J Med Imaging Radiat Oncol*. 2014 Oct;58(5):625-32. doi: 10.1111/1754-9485.12198. Epub 2014 Jun 19.
11. Wan KM, Rhou YJJ, **Berges, T**, Campbell N, **Carter J, Anderson L, Pather S**. Pelvic actinomyces mimicking ovarian cancer: a report of 3 cases and review of the literature. *Austin J Obstet & Gynecol* 2014;1(3):1-3

12. Thiruthaneeswaran N, Turner S, **Milross C**, Gogna K. Promoting a research culture among junior radiation oncologists: outcomes from the introduction of the Australian and New Zealand research requirement in training. *Clin Oncol (R Coll Radiol)*. 2014 Mar;26(3):162-73.

International Presentations

1. **Anderson L**. Smooth muscle tumours of uterus, oral presentation, Annual General Meeting, New Zealand Society of Pathology, Hamilton New Zealand, October 2014.
2. **Anderson L**. Adenosarcoma with sarcomatous overgrowth, oral presentation, Annual General Meeting, New Zealand Society of Pathology, Hamilton New Zealand, October 2014.
3. **Anderson L**. Primary peritoneal carcinoma, oral presentation, Annual General Meeting, New Zealand Society of Pathology, Hamilton New Zealand, October 2014.
4. **Anderson L**. Molecular update on serous adenocarcinomas, for oral presentation, Annual General Meeting, New Zealand Society of Pathology, Hamilton New Zealand, October 2014.
5. **Anderson L**. Adenosarcoma with sarcomatous overgrowth, oral presentation, XXXth Congress of the International IAP, Bangkok Thailand, October 2014.
6. **Anderson L**, Selinger YB, **Carter J**, O'Toole S, **Beale P**. Oncogene mutation testing in low grade serous adenocarcinomas of ovary and borderline ovarian tumours in an Australian tertiary care referral setting. Poster presentation. Int Gyn Cancer Society. Melbourne Australia. 8th - 11th November 2014.
7. Davis G, Anderson I, **Pather S**. Oral poster presentation Extramammary Pagets disease of the cervix mimicking carcinoma on cytology. RCOG World Congress 2015. Joint RCOG/RANZCOG Event. Brisbane Convention and Exhibition Centre, Australia 12-15 April 2015.
8. Morton R, **Pather S**. Oral Poster Presentation (Accepted Dec 2014)The Great Mimicker: Peritoneal Tuberculosis RCOG World Congress 2015: Joint RCOG / RANZCOG Event, Brisbane Convention and Exhibition Centre, Australia, on 12-15 April 2015.
9. **Tejada-Berges T**. Cervical Cancer Screening as an Effective Model of a Screening test. Advanced Course in Medical Education, Hoc Mai Foundation/University of Sydney, Hanoi, Vietnam, 10th September, 2014.
10. **Tejada-Berges T**. Writing an Academic CV: Putting Your Best Foot Forward. Advanced Course in Medical Education, Hoc Mai Foundation/University of Sydney, Hanoi, Vietnam, 11th September 2014.

National Presentations

1. **Anderson L**, Yu B, Sellinger C, **Carter J**, O'Toole S and **Beale P**. Oncogene mutation testing in low grade serous adenocarcinomas of ovary and borderline ovarian tumours in an Australian tertiary care

- referral setting. Poster presentation at the 15th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2014) November 8-11, Melbourne, Australia, 2014.
2. **Anderson L.** Gynaecological cytology, Oral presentation, Glandular lesions on ThinPrep cytology, Australian Society of Cytology Annual General Meeting, Darwin, October 2014.
 3. **Anderson L.** Hereditary gynaecological malignancies, Guest lecture, Oral presentation, Gynaecological Pathology Companion Club, 39th International Scientific Meeting of the Australasian Division of the International Academy of Pathology, 2014.
 4. **Anderson L.** Molecular update on serous adenocarcinomas, Oral presentation, Combined RPAH MD Anderson Course, Sydney, February 7-9th, 2014.
 5. Blain G, **Pather S, Richards A, Carter J, Saidi S.** Outcomes for women presenting with high grade pap smears: Implications for “see and treat”. Oral presentation Combined ANZGOG/ASGO ASM. Canberra 26-29 March 2014
 6. Farrell R, **Carter J**, Dixon S, Webb P. Lymphadenectomy in early stage high-risk endometrial cancer: clinical characteristics and outcomes in an Australian cohort. Oral presentation Combined ANZGOG/ASGO ASM. Canberra 26-29 March 2014
 7. Mizrahi D, Naumann P, Broderick C, **Beale P, Harrison M**, Ryan M and Friedlander M. An exercise intervention during chemotherapy for women with recurrent ovarian cancer. ANZGOG ASGO Combined Annual Scientific Meeting 2014 (Abst 22)
 8. Nagrial A, Long A, Chin V, **Carter J, Beale P.** Duration of systemic therapy for ovarian cancer: a systematic review and meta-analysis. Oral presentation Combined ANZGOG/ASGO ASM. Canberra 26-29 March 2014
 9. Nagrial A, Chin V, Long A, **Carter J**, Beale P. Duration of systemic therapy for ovarian cancer: A systematic review and meta-analysis. Oral presentation ASCO. 30th May-3rd June 2014, Chicago, Illinois. USA. Abstract5549. J Clin Oncol 32:5s, 2014 (suppl; abstr 5549)
 10. **Pather S.** Colposcopy. Oral presentation. Management of Cervical Glandular abnormalities. Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May
 11. **Pather S.** Colposcopy. Oral presentation. Management benign vulval conditions. Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May
 12. **Pather S.** Colposcopy. Oral presentation. Early invasive cervical cancer. Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May
 13. **Pather S.** Colposcopy. Panel discussion. Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May
 14. **Pather S.** Colposcopy. Oral presentation. Early invasive cervical cancer. Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May
 15. **Pather S.** Colposcopy. Oral presentation. Management of complications of dysplasia treatment. Australian Society of Colposcopy

and Cervical Pathology treatment course. RPA Hospital, Camperdown, 25th October 2

16. **Richards A, Herbst U, Pather S, Saidi S, Tejada-Berges T**, Williams P, Tan K, **Carter J**. HE4, CA125, the Risk of Malignancy Algorithm (ROMA) and the Risk of Malignancy Index (RMI) and complex pelvic masses - a prospective comparison in the pre-operative evaluation of adnexal and pelvic masses in an Australian population. Accepted for E-poster presentation at RCOG World Congress 2015: Joint RCOG/RANZCOG Event, Brisbane, QLD, 12-15 April 2015
17. **Tejada-Berges T**. Can I still have children, doctor? Fertility-sparing Options for Women Diagnosed with Gynaecologic Cancers. Oral presentation at 10th Annual Educational Symposium of the Lifehouse Gynaecologic Oncology Group. 4th April 2014.
18. **Tejada-Berges T**. Gynaecological Cancer in Pregnancy. Oral Presentation, ACI Gynaecological Oncology Nurses Group, RPAH, Camperdown, 16th May 2014.
19. **Tejada-Berges T**. Ovarian Cancer Risk-Reduction Treatment Options. Oral Presentation, 14th Annual BRCA Information Day, Association of Genetic Support of Australasia, Sydney, 12th October 2014.

Local Presentations

1. **Anderson L**. Placental pathology, Oral presentation, University of Western Sydney Pathology Course for national pathology registrars, 2014.
2. **Anderson L**. Biology of cancer lecture, Oral presentation to University of Sydney Nursing Students, Royal Prince Alfred Hospital, 6th May, 2014.
3. **Anderson L**. Placental pathology, Oral presentation to high risk obstetric morbidity and mortality meeting, Royal Prince Alfred Hospital, 24th May, 2013.
4. **Carter J**. An overview of apparent early stage cancer of uterine corpus. Presentation Medical Oncology Journal Club. Lifehouse. 10th June 2014
5. **Philp S**. Nurses Leading the Way: Nurse Led Care at Lifehouse, Lifehouse Gynaecologic Oncology Group, 10th Annual Educational Symposium: A New Beginning, A New Way of Care, Lifehouse, April, 2014.
6. **Saidi, S**. Trends in Surgery – is More Always Better? Oral presentation, Lifehouse Annual Symposium, 4th March 2014.

Abstracts

1. Adhikari C and **Anderson L**. Muir-Torre syndrome: a case report, Poster presentation, Updates, Melbourne, 2014, Abstract in Pathology, February 2014, volume 46, doi10.1097/01.PAT.0000443528.94613.56.
2. McLaren E, White K, Eakin E, **Philp S**. A Nurse-Led Intervention for Women Following a Diagnosis of Type 1 Endometrial Cancer, Flinders

Centre for Innovation in Cancer Survivorship Conference, Adelaide, SA, 6-7th February, 2015 (submitted)

3. Nagrial A, Chin V, Long A, **Carter J**, Beale P. Duration of systemic therapy for ovarian cancer: A systematic review and meta-analysis. Oral presentation ASCO. 30th May-3rd June 2014, Chicago, Illinois. USA. Abstract5549. J Clin Oncol 32:5s, 2014 (suppl; abstr 5549)

Invited Lectureship, Guest or Program Chair

1. **Anderson L.** Invited Gynaecological Pathology Workshop over 7-8 May, Royal Hobart Hospital, Hobart Tasmania, May 2014.
2. **Anderson L.** Invited National Representative for National Coalition of Public Pathology (NCOPP) for "Consultation session on the renewal of the National Cervical Screening Program. Department Health, Australian Government Canberra. 25th November 2014
3. **Carter J.** Invited Speaker. Postgraduate Seminar Hong Kong College of Obstetricians & Gynaecologists. Optimising Recovery After Surgery. Hong Kong. 9th March 2014
4. **Carter J.** Invited Speaker. Postgraduate Seminar Hong Kong College of Obstetricians & Gynaecologists. An Overview of Apparent Early Endometrial Cancer. Hong Kong. 9th March 2014
5. **Carter J.** Invited Speaker. University of Hong Kong. Department of Obstetrics and Gynaecology. An Overview of Apparent Early Endometrial Cancer. Hong Kong. 12th March 2014
6. **Carter J.** Program Chair. 10th Annual Advances in Gynaecological Oncology. 4th April 2014
7. **Carter J.** An overview of apparent early stage cancer of uterine corpus. Presentation Medical Oncology Journal Club. Lifehouse. 10th June 2014
8. **Pather S.** Session 2 Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May 2014
9. **Pather S.** Session 1: Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May 2014
10. **Harrison M.** Co-chair – Guest speakers and Oral Abstracts ANZGOG ASGO Combined Annual Scientific Meeting 2014
11. **Harrison M.** RCC: Clinical Trials to Real World Patient Outcomes. Clinical case presentation. May 2014, Sydney, Australia
12. **Harrison M.** ANZGOG consumer engagement session. Practicalities of trials from a researchers perspective as it impacts trial participants. Sept 2014, Sydney Australia
13. **Richards A.** Screening in Gynaecological Cancers. Diploma examination revision course, RANZCOG, Rydges Hotel, North Sydney 25 November 2014
14. **Richards A.** Dysplasia and the Management of Abnormal Pap Smear, Diploma examination revision course, RANZCOG, Rydges Hotel, North Sydney 25 November 2014

Grants and Awards (+/-Submitted)

1. **Anderson L** (CI), Gupta R (CI), O'Toole S (CI), **Carter J** (AI) Clark J (AI), Sydney Local Health District Cancer Services Research Grant for the study of Next Generation Sequencing of HPV driven cervical carcinomas. The study is a collaborative venture with Head and Neck HPV driven carcinomas. \$60,000.
2. Hoffmann P, Oehler M, Kock I, Ruzkiewicz A (CI), **Carter J** (AI). Defining a molecular signature of metastasis in gynaecological cancer. Project Grant 2015. Application ID:1086933. Defining a molecular signature of metastasis in gynaecological cancer. NHMRC 2014
3. Hoffmann, Oehler, Koch, Ruzkiewicz (CI), **Carter J** (AI). Project Grant 2015. Application ID:1086933. Defining a molecular signature of metastasis in gynaecological cancer. NHMRC 2014
4. **Carter J**. Article "A 5-Year review of gynaecological oncology patients managed by a fast track surgery program" chosen and promoted on Scientific Research Publishing newsletter.
http://image.ljemail.org/archive/nl20140117en.htm?utm_campaign=nl20140117en

Research Supervision

1. **Carter J**. Thesis Review. Strategies for improving cervical cancer screening in Laos. Dr Sivixay Thammalangsy. 2014. Prematurely ceased.
2. **Carter J**. Thesis Review. Lymphadenectomy in early stage high risk endometrial cancer: clinical characteristics and outcomes in an Australian cohort. Dissertation Masters of Surgery. Dr Rhonda Farrell. 23rd March 2014
3. **Carter J**. PhD Supervision. Dr Rachael Rodgers. The ex vivo stimulation of ovaries to facilitate oocyte collection prior to gonadotoxic treatment. The University of Sydney. 2014
4. **Carter J**. CGO Thesis supervision Dr Archana Rao. Venous Thromboembolism Prophylaxis and Surgery for Gynaecological Malignancy – a survey of clinical practice of Certified Gynaecological Oncologists in Australia and New Zealand. 7th July 2014
5. **Pather S**. Research supervision of Dr Davis on cytological prediction of Pagets disease of the cervix.
6. **Pather S**. Research supervision of Dr Morton on peritoneal tuberculosis mimicking gynaecologic cancer
7. **Pather S**. Research supervision of Dr Wan on pelvic actinomycosis.
8. **Pather S**. Research supervision of Dr Naidu from the University of Pretoria in South Africa on Quality of life in vulval cancer.
9. **Pather S**. Clinical Observership Supervisor for Dr Ronald Latap as part of the International Gynaecological Cancer Society October 2014
10. **Philp S**. Associate Supervisor for Doctor of Philosophy Candidate: Testing the feasibility of a brief nurse-led lifestyle intervention for women with type 1 endometrial cancer, School of Nursing, The University of Sydney

11. **Philp S.** Primary Supervisor. Sydney Nursing School, Summer Scholar: The Gynaecology Nurse Practitioner Role, Literature review.
12. **Philp S.** Academic adviser for Master of Cancer and Haematology Nursing Research Thesis Student, Management of postembolisation syndrome in patients who have undergone hepatic transarterial chemoembolisation (TACE) for liver primary neoplasms or liver metastases
13. **Saidi S.** Supervision of Dr Rhett Morton. Utility of frozen section in the management of adnexal masses
14. **Saidi S.** Supervision of Dr Gemma Blain. Outcomes for women presenting with high grade pap smears - implications for “see and treat”.

Ethics Approved Studies

1. Rasko J, Marshall A, Bailey C, **Anderson L, Pather S, Richards A.** Role of CTCF mutations in endometrial cancer.
2. **Anderson L, Oehler M, Carter J, and Hoffmann P,** Proteomic characterization of Endometrial Carcinoma using MALDI technique.
3. **Pather S.** Protocol C13-0268. The conservative management of young women up to the age of 2 with cervical intraepithelial neoplasia 2. The prediction of regression (Princess Study). Accepted 07 August 2014
4. **Richards. A and Anderson L,** HE4 and Pax-8 in endometrial tumours and malignant ascites.
5. **Anderson L, O’Toole S, Beale P, Carter J.** Oncogene testing of serous borderline tumours and low grade serous adenocarcinomas of ovary.
6. **Harrison M.** Uptake of invitation to enrol on CART-WHEEL.ORG from Lifehouse and impact on recruitment to CART-WHEEL.ORG for patients with rare gynaecological cancers
7. Morton R, **Saidi S.** Utility of frozen section in the management of adnexal masses
8. **Richards A, Pather S, Williams P, Carter J.** HE4, CA125 and pelvic mass - a prospective comparison of the Risk of Malignancy Algorithm (ROMA) and the Risk of Malignancy Index (RMI) in the pre-operative evaluation of adnexal and pelvic masses. (Protocol X12-0266).
9. **Richards A, Pather S, Williams P, Carter J.** HE4 in gynaecological malignancies. (Protocol amendment for X12-0266).
10. **Richards A, Pather S, Williams P, Carter J.** Effect of HE4 monitoring and response to chemotherapeutic treatment for patients with primary Epithelial Ovarian Carcinoma (Protocol amendment for X12-0266).
11. **Richards A, Pather S, William P, Carter J.** Effect of HE4 monitoring and response to chemotherapeutic treatment for patients with recurrent Epithelial Ovarian Carcinoma (Protocol amendment for X12-0266).
12. **Richards A, Anderson L, Carter J.** The role of HE4 and PAX8 immunohistochemistry in endometrial curettage and hysterectomy specimens (Protocol X13- 0233).

13. **Richards A, Anderson L, Carter J.** The role of HE4 and PAX8 in malignant ascites and disseminated intraperitoneal malignancy (Protocol X13-0234).
14. **Tejada-Berges T.** Women's Health after Surgical Menopause Study (protocol submitted for ethics approval).
15. **Tejada-Berges T.** Anal cytological, histological and HPV distributions in women with a history of high grade cervical/vulval/vaginal disease (protocol submitted for ethics approval).
16. **Tejada-Berges T, Duncan R, Richards T, Carter J, Philp S.** Study Evaluating the potential to eliminate redundant tests after a diagnosis of molar pregnancy to reflect a changing clinical picture (protocol submitted for ethics approval).

Grant, Trial, Thesis & Manuscript Reviews

1. **Anderson L.** Examination of an MPhil thesis for University of Sydney in April 2014, on the characterization of circulating and endometrial dendritic cell populations in fertile and infertile women with and without endometriosis.
2. **Anderson L.** Manuscript number PAT-D-14-00290, Pathology 13th November, 2014
3. **Anderson L.** Manuscript number PAT-D-14-00195, Pathology, 2nd August, 2014.
4. **Anderson L.** Manuscript IMP3 signatures, Journal of Haematology and Oncology, June, 2014.
5. **Carter J.** Thesis Review. Strategies for improving cervical cancer screening in Laos. Dr Sivixay Thammalangsy. 2014. Prematurely ceased.
6. **Carter J.** Thesis Review. Lymphadenectomy in early stage high risk endometrial cancer: clinical characteristics and outcomes in an Australian cohort. Dissertation Masters of Surgery. Dr Rhonda Farrell. 23rd March 2014
7. **Carter J.** PhD Supervision. Dr Rachael Rodgers. The ex vivo stimulation of ovaries to facilitate oocyte collection prior to gonadotoxic treatment. The University of Sydney. 2014
8. **Carter J.** CGO Thesis supervision Dr Archana Rao. Venous Thromboembolism Prophylaxis and Surgery for Gynaecological Malignancy – a survey of clinical practice of Certified Gynaecological Oncologists in Australia and New Zealand. 7th July 2014
9. **Carter J.** Manuscript Review. IJG-D-14-00044. 13th January 2014
10. **Carter J.** Manuscript Review. MJA14.00021. 15th January 2014
11. **Carter J.** Manuscript Review. AOGS-14-0010. 3rd February 2014
12. **Carter J.** Manuscript Review. UOG-2014-0038. 8th February 2014
13. **Carter J.** Manuscript Review. ANS-2014-00145. 13th February 2014
14. **Carter J.** Manuscript Review. ANZJOG-2014-0024. 13th February 2014.
15. **Carter J.** Manuscript Review. CJOG-2012-0793. 15th February 2014
16. **Carter J.** Manuscript Review. AOGS-14-0139. Acta Obstetrica et Gynecologica Scandinavica 4th March 2014.
17. **Carter J.** Clinical Trial Review. Protocol X14-0129. 19th April 2014

18. **Carter J.** Manuscript ID ANZJOG-2014-0134. 8th May 2014
19. **Carter J.** Manuscript ID CJOG-2014-0331. 12th May 2014
20. **Carter J.** Manuscript ID CJOG-2014-0285. 1st June 2014.
21. **Carter J.** Manuscript APJCO-2014-0131. 4th June 2014
22. **Carter J.** Manuscript CJOG-2014-0491. 27th June 2014.
23. **Carter J.** Manuscript CJOG-2014-0490. Journal of Obstetrics and Gynaecology. 7th July 2014
24. **Carter J.** Manuscript ANZJOG-2014-0154. 6th August 2014
25. **Carter J.** Manuscript IJG-D-14-01252. 13th November 2014
26. **Carter J.** Manuscript W14-1087. American Journal of Obstetrics and Gynecology. 28th December 2014
27. **Pather S.** ANZJOG-2013-0415. 4 Jan 2014
28. **Pather S.** ANZJOG-2014-0091. Australian and New Zealand Journal of Obstetrics and Gynaecology. 23rd Feb 2014
29. **Pather S.** ANZJOG-2014-0217. 04 April 2014
30. **Pather S.** Obstetric Case Reports. Dec 2014.
31. **Pather S.** Borderline Epithelial tumour of the ovary. A review of 55 patient, Journal of Obstetrics and Gynaecology. July 2014
32. **Pather S.** Grant Review . Femme: A Phase II Randomised Clinical Trial of Mirena® ± Metformin Weight Loss Intervention in Patients with Early Stage Cancer of the Endometrium. NZ Gynaecologic Research Fund. \$5000 26th May 2014
33. **Pather S.** Grant Review. Femme: Culturing primary ascitic ovarian cancer cells on 3D collagen gels to evaluate drug responsiveness in chemo-naïve and resistant patients. NZ Gynaecologic Research Fund. \$5000 26th May 2014
34. **Pather S.** Grant Review . Femme: A prospective audit of sentinel node biopsy for patients with vulval cancer in Australia and New Zealand. NZ Gynaecologic Research Fund. \$5000 26th May 2014
35. **Philp S.** Abstract Review. International Society of Nurses in Cancer Care (ISNCC), 18th Annual International Conference on Cancer Nursing, Panama City: Panama, 7-11 September, 2014.
36. **Philp S.** Abstract review. International Gynecologic Cancer Society (IGCS) Nursing and Supportive Care Forum, Melbourne, Vic, 7th November 2014
37. **Philp S.** Abstract review. Australian College of Nurse Practitioners (ACNP) Conference, Sydney, NSW, September 2014
38. **Philp S.** Journal of Clinical Nursing, manuscript review, Manuscript ID JCN-2014-0694
39. **Philp S.** Journal of Clinical Nursing, manuscript review, Manuscript ID JCN-2014-0796
40. **Philp S.** Journal of Clinical Nursing, manuscript review, Manuscript ID JCN-2014-0071
41. **Philp S.** Master of Cancer and Haematology Nursing Research Thesis, Management of postembolisation syndrome in patients who have undergone hepatic transarterial chemoembolisation (TACE) for liver primary neoplasms or liver metastases.

42. **Saidi S.** Manuscript Number ANZJS - ANS-2014-00971. Australian and New Zealand Journal of Obstetrics and Gynaecology. 1st November 2014.

Appointments

1. **Carter J.** Scientific Advisory Panel The Australian Gynaecological Cancer Foundation. 24th February 2014.
2. **Carter J.** Scientific Advisor Panel. Compass Trial. A randomized controlled trial of primary HPV DNA testing for cervical screening in Australia. March 2014
3. **Carter J.** Health Care Complaints Commission's expert advisers panel. 19th March 2014
4. **Carter J.** Editorial Board Member Austin Journal of Obstetrics and Gynecology. 1st February 2014
5. **Pather S.** Editorial Board Member Austin Journal of Obstetrics and Gynecology. 1st April 2014
6. **Pather S.** Member of the Human Research Ethics Committee at Sydney Area Health Service. May 2014
7. **Richards A.** Membership of Psycho Oncology Co-operative Research Group
8. **Tejada-Berges T.** September 2014: Clinical Associate Professor, University of Sydney Medical School, Central Clinical School, Discipline of Obstetrics, Gynaecology & Neonatology.

Administrative Responsibilities

1. **Anderson L.** Head of Cytology, Royal Prince Alfred Hospital.
2. **Carter J.** Department Head Gynaecological Oncology. Lifehouse
3. **Carter J.** Committee Member. MDAC. Lifehouse
4. **Carter J.** Committee Member. Clinical Leadership Committee. Lifehouse
5. **Carter J.** Committee Member. RPAH Theatre Procedures Committee.
6. **Carter J.** Committee Member. Standards Setting: Patient Identification. Lifehouse
7. **Carter J.** Scientific Advisory Panel The Australian Gynaecological Cancer Foundation. 24th February 2014.

Course Organisation

1. **Carter J, Philp S, Tejada-Berges T, Young C.** Course Convenor. 10th Annual Advances in Gynaecological Oncology Symposium: A New Beginning, A New Way of Care. 4th April 2014
2. **Pather S.** Organiser ASCCP Course. Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May 2014
3. **Pather S.** ASCCP Treatment Course. Australian Society of Colposcopy and Cervical Pathology treatment course. RPA Hospital, Camperdown, 25th October 2014

4. **Philp S.** Lecturer and Course Coordinator, Cancer and Haematology Nursing, Sydney Nursing School, The University of Sydney
5. **Philp S.** Organising Committee. ACI GONG, "Gynaecological Cancers 10 years on", RPAH, 16th May 2014
6. **Philp S.** Clinical Stream Coordinator, Cancer and Aged Care, The 9th Conference of The Australian College of Nurse Practitioners, 'New Frontiers: Building future generations, Sydney, September 2014
7. **Richards A.** Assistant for ASCCP Colposcopic Treatment Course, RPAH, 25th October 2014.
8. **Tejada-Berges T.** Assistant for ASCCP Colposcopic Treatment Course, RPAH, 25th October 2014.

Committee Membership

1. **Anderson L.** Royal College of Pathologists of Australasia, RCPAQAP Gynaecological Pathology Quality Program, 2014.
2. **Anderson L.** Invited National Representative for National Coalition of Public Pathology (NCOPP) for "Consultation session on the renewal of the National Cervical Screening Program. Department Health, Australian Government Canberra. 25th November 2014
3. **Anderson L.** Organizing Committee, 9th Asia Pacific International Academy of Pathology Congress, Brisbane 2015.
4. **Harrison M.** Australian and New Zealand Gynaecological Oncology Group. Quality assurance committee
5. **Harrison M.** Australian and New Zealand Gynaecological Oncology Group. Ovarian cancer working group
6. **Richards A.** Research Advisory Committee for RANZCOG.
7. **Richards A.** Ovarian Tumour-type work Research advisory group, ANZGOG.
8. **Philp S.** NSW ACI Gynaecological Oncology Nurses Group (GONG) Executive Committee
9. **Philp S.** ICGS Nursing and Supportive Care Forum Organising Committee
10. **Philp S.** Australian College of Nurse Practitioners (ACNP) 2014 Conference Organising Committee Cancer Stream
11. **Philp S.** Lifehouse, Inpatient Forms Committee
12. **Philp S.** Lifehouse, Falls Prevention Standard, Working Party
13. **Philp S.** Lifehouse/SLHD Lymphoedema Focus Group
14. **Philp S.** Sydney Nursing School, Local Disability Action Plan, Working Party
15. **Saidi S.** ANZGOG Cervical Tumour Type Working Group.
16. **Saidi S.** Governance Working Group of ASGO.
17. **Saidi S.** British Gynaecological Cancer Society surveys peer review committee.

Selection Committees

1. **Anderson L.** Cytology Scientist In-charge Interview. July 2014.
2. **Anderson L.** Staff Specialist Interview. November 2014.

3. **Carter J.** Clinical Trials Nurse. 16th-17th January 2014
4. **Carter J.** Clinical Trials Nurse. 19th June 2014

Media & Fund Raising

1. **Carter J.** Interview Modern Medicine. Long term outcomes for women treated for cervical precancer. 22nd Jan 2014
2. **Carter J.** Invited speaker. Trailblazer Appreciation Function. 16th December 2014

College Activities; Lectures

1. Brand A, Do V, Harnett P and **Anderson L**, Gynaecological Pathology Tumour Board Oral Presentation, October 2014, Rydges Hotel for MRANZCOG registrars.
2. **Pather S.** Examiner for the CGO subspeciality in Gynaecologic Oncology. July 2014
3. **Richards A.** Screening in Gynaecological Cancers. Diploma examination revision course, RANZCOG, Rydges Hotel, North Sydney 25 November 2014
4. **Richards A.** Dysplasia and the Management of Abnormal Pap Smear, Diploma examination revision course, RANZCOG, Rydges Hotel, North Sydney 25 November 2014
5. **Richards A.** Review of 4 FRANZCOG trainee research proposals. RANZCOG Research Advisory Committee
6. **Tejada-Berges T.** MRANZCOG Revision Course: Surgical Pelvic Anatomy, Rydges Hotel, North Sydney, 27th October 2014.

University Activities

1. **Carter J.** Registration as Auxillary Supervisor (Associate Supervisor) of Higher Degree Research Candidates at Sydney Medical School. 26th February 2014.
2. **Carter J.** External examiner for University of Hong Kong MBBS Examination. 10th-14th March 2014
3. **Carter J.** Associate PhD Supervision. Dr Rachael Rodgers. The ex vivo stimulation of ovaries to facilitate oocyte collection prior to gonadotoxic treatment. The University of Sydney. 2014
4. **Carter J.** SCORPIO: HPV and Vaccination. 20th October 2014
5. **Pather S.** Cervix Cancer SCORPIO. Organiser 20th October 2014.
6. **Pather S.** Management of the abnormal pap smear. Medical Student Lecture KPEC RPA Hospital 18/03/14
7. **Pather S.** Management of Postmenopausal Bleeding. Medical Student Lecture KPEC RPA Hospital 18/03/14
8. **Pather S.** Management of the abnormal pap smear. Medical Student Lecture KPEC RPA Hospital 20/05/14
9. **Pather S.** Management of Postmenopausal Bleeding. Medical Student Lecture KPEC RPA Hospital 20/05/14

10. **Pather S.** Management of the abnormal pap smear. Medical Student Lecture KPEC RPA Hospital 22/07/14
11. **Pather S.** Management of Postmenopausal Bleeding. Medical Student Lecture KPEC RPA Hospital 22/07/14
12. **Pather S.** Management of the abnormal pap smear. Medical Student Lecture KPEC RPA Hospital 07/10/14
13. **Pather S.** Management of Postmenopausal Bleeding. Medical Student Lecture KPEC RPA Hospital 07/10/14
14. **Philp S.** Lecturer and Course Coordinator, Cancer and Haematology Nursing, Sydney Nursing School, The University of Sydney
15. **Philp S.** Meeting with ANMAC regarding Nurse Practitioner Education and reaccreditation of Master of Nursing (Nurse Practitioner), Sydney Nursing School.
16. **Richards A.** SCORPIO: Histopathology of dysplasia and cervical cancer. 20th October 2014
17. **Tejada-Berges T.** Lecture: Evaluation of the Adnexal Mass. 21st March 2014.
18. **Tejada-Berges T.** Lecture: Evaluation of the Adnexal Mass. 23rd May 2014.
19. **Tejada-Berges T.** Lecture: Evaluation of the Adnexal Mass. 24th July 2014.
20. **Tejada-Berges T.** Lecture: Evaluation of the Adnexal Mass. 10th October 2014.
21. **Tejada-Berges T.** Cervix Cancer Scorpio Lecture: Clinical Staging of Cervix Cancer. 20th October 2014.
22. **Tejada-Berges T.** Cervix Cancer Scorpio Lecture: Management of Cervix cancer. 20th October 2014.
23. **Tejada-Berges T.** Lecture on Hereditary Breast and Ovarian Cancer Syndrome, University of Sydney Medical School, Postgraduate Course in Reproductive Health Sciences and Human Genetics. 12th August, 2014.
24. **Tejada-Berges T.** Tutor for Problem-Based Learning, Block 1 Foundation Block, University of Sydney Medical School, March 13, 20 and 27, April 3 and 10, 2014.
25. **Saidi S.** Cervical Cancer Screening and Management of the Abnormal Pap Smear. Presentation University of Sydney Medical School. 27th October 2014
26. **Saidi S.** SCORPIO session training. University of Sydney Medical School 27th October 2014.
27. **Saidi S.** Tutor in clinical oncology. University of Sydney Medical Students 21st October – 4th November 2014.
28. **Saidi S.** Medical Student PPD interviews. University of Sydney Medical School. 16th – 17th July 2014.

Courses/Conferences Attended

1. **Anderson L.** MD Anderson RPAH Pathology Course, March, 2014.
2. **Anderson L.** Australasian Division of the International Academy of Pathology Meeting, Brisbane, June, 2014.
3. **Anderson L.** Australian Society of Cytology Annual General Meeting, Darwin, October 2014.
4. **Anderson L.** XXXth Congress of the International IAP, Bangkok Thailand, October 2014.
5. **Anderson L.** Annual General Meeting, New Zealand Society of Pathology, Hamilton New Zealand, October 2014.
6. **Anderson L.** 15th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2014) November 8-11, Melbourne, Australia, 2014.
7. **Carter J.** Attended and Invited Speaker. Postgraduate Seminar Hong Kong College of Obstetricians & Gynaecologists. Optimising Recovery After Surgery. Hong Kong. 9th March 2014
8. **Carter J.** Attended and Invited Speaker. Postgraduate Seminar Hong Kong College of Obstetricians & Gynaecologists. An Overview of Apparent Early Endometrial Cancer. Hong Kong. 9th March 2014
9. **Carter J.** Attended and Invited Speaker. University of Hong Kong. Department of Obstetrics and Gynaecology. An Overview of Apparent Early Endometrial Cancer. Hong Kong. 12th March 2014
10. **Carter J.** Attended. ANZGOG/ASGO Combined Annual Scientific Meeting. Hyatt Hotel Canberra. 26-29th March 2014. Approved 26 CPD Points
11. **Harrison M.** ANZGOG/ASGO Combined Annual Scientific Meeting. Canberra, Australia 26th – 30th March 2014
12. **Harrison M.** 15th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2014) November 8-11, Melbourne, Australia, 2014.
13. **Pather S.** Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May 2014
14. **Pather S.** Australian Society of Colposcopy and Cervical Pathology treatment course. RPA Hospital, Camperdown, 25th October 2
15. **Pather S.** Inaugural Peritonectomy Conference St George Hospital Sydney. 4-5 November 2014
16. **Philp S.** Cancer Nurse Practitioners of Australia, Masterclass, Lifehouse, March 2014
17. **Philp S.** ACI GONG, "Gynaecological Cancers 10 years on", RPAH, 16th May 2014
18. **Philp S.** ICGS and CNSA Nursing and Supportive Care Forum, Melbourne, Vic, 7th November, 2014
19. **Philp S.** ICGS 15th Biennial Meeting, Melbourne, Vic, 8-11th November, 2014
20. **Richards A.** Attended. ANZGOG/ASGO Combined Annual Scientific Meeting. Hyatt Hotel Canberra. 26-29th March 2014. Approved 26 CPD Points
21. **Saidi S.** Joint ANZGOG and Australian Society of Gynaecologic Oncologists Annual Scientific Meeting. Canberra, 26th-29th March 2014.

22. **Saidi S.** 15th Biennial meeting of the IGCS. Melbourne, 8th-11th November 2014.
23. **Saidi S.** C-Quip certification for the ASCCP. 20th October 2014.
24. **Tejada-Berges T.** ANZGOG/ASGO Combined Annual Scientific Meeting. Canberra, Australia 26th – 30th March 2014.
25. **Tejada-Berges T.** 15th Biennial Meeting of the International Gynecologic Cancer Society. Melbourne, Australia. 8th-11th November 2014.

Trials List

Gynaecological Oncology Clinical Trials List	Presenter	Comment
Ovary		
LH14.018: ICON 8 . An international phase 3 randomised trial of dose fractionated chemotherapy compared to standard 3 weekly chemotherapy following immediate primary surgery or as part of delayed primary surgery for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer	Beale & Harrison	Approached: 3 Recruited: 1 Active: 1 Site activated 29 August 2014 Recruitment suspended 27 November 2014
LH14.029: MEKi012 : Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated Unresectable Low Grade Ovarian Cancer	Beale & Harrison	Enrolment stopped by sponsor (16 Dec 2014)
LH14.024: OVAR 2.21 : A prospective randomized Phase III trial of carboplatin/ gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.	Beale & Harrison	Site activated 18 Sep 2014 Approached: 3
X14.0215: feMMe study A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients with Early Stage Cancer of the Endometrium (ANZGOG 1301)	Carter	Awaiting update from Ethics
Identification of protein markers suitable for early detection of ovarian cancer	Beale Dalrymple Carter Pather	Open; RPA: 344 P.B to draft letter to investigator – keen to continue participating ?Transition in Feb2015
HE4/ROMA Index Study	Richards	Open; RPA:46 LH SSA Pending
HE4 and gynaecological malignancies : analysis of the significance of HE4 in suspected ovarian carcinoma and its relationship with endometrial, vulval, vaginal, cervical and GTD.	Richards	Open; LH SSA Pending EN:6, CE:3
HE4 kinetics : effect of HE4 monitoring and response to primary chemotherapeutic treatment for patients with epithelial ovarian carcinoma	Richards	Open; LH SSA Pending
HE4 kinetics : effect of HE4 monitoring and response to chemotherapeutic treatment for patients with recurrent epithelial ovarian carcinoma	Richards	Open; LH SSA Pending
LH13.003: PARAGON : Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms	Beale & Harrison	Recruited: 30 Active: 5 Off-treatment: 18

		Deceased: 7 Potential: 2 (as of 22/12/14)
X14-0396: WHAM : Impact of risk reducing bilateral salpingoophorectomy on non-cancer outcomes in high risk young women: a multicentre prospective trial	Tejada-Berges	Reply received 17/12/14 - Queries to be addressed by TTB and CM
Prediction of high grade cervical dysplasia on histopathology in patients with HSIL on pap smear	Blain & Saidi	For analysis and writing up
INOVAte : Individualised Ovarian cancer Treatment Through Integration of Genomic Pathology into Multidisciplinary Care	Beale	Grant application submitted – feedback pending April 2015
Corpus		
STATEC : A randomized trial of Lymphadenectomy to direct adjuvant therapy in high risk endometrial cancer. An international trial developed by the Gynaecological Cancer Inter Group (GCIG).	Saidi	Has ANZGOG approval – NEAF to be submitted; recommended to submit to RPAH or Concord HREC
Cervix		
LH13.056: OUTBACK : ANZGOG 0902: A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone.	Beale	Recruited: 3 Active: 2 Follow-up: 0 Deceased: 1 Brachytherapy dosing issue – cannot comply with protocol
Dysplasia		
X13-0268: PRINCESS2 : The prediction of regression in CIN2	Pather	Contractual issues; discussions still ongoing- still waiting for local district to review MOU
Anal cytological and HPV distribution in women with a history of high grade cervical/vulval/vaginal disease	Tejada-Berges	Still going through ethics
Vulva		
Other		
HPV self-testing	Herbst	Resubmitted to RPA HREC on 26 November

		2014
Centre for Analysis of Rare Tumours (CART-WHEEL)	Harrison	LNR submitted to HREC – No response yet
X14-0344 & LNR/14/RPAH/465 – Maintenance of a Gynaecologic Oncology database and patient management system	Gynaecological Oncology	LNR submitted; S.S. to address queries (3 Dec 14)
Clinical audit of single surgeon experience with Fast Track Surgery in gynaecological patients	Carter	LNR submitted to RPA HREC
Carbohydrate Loading in Gynaecologic Oncology Open Surgery	Saidi	Queries to be addressed
Studies in Follow Up Phase		
LH13.039: OVAR12 . Multicentre randomised double blind Phase 3 trial to investigate the efficacy of and safety of BBIF 1120 in combination with carboplatin and Paclitaxel compared to placebo plus carboplatin and Paclitaxel in patients with advanced ovarian cancer	Beale	Transferred to LH 12/12/13. 2 pts remain in follow-up
LH13.036: OVAR 16 : Pazopanib, an oral angiogenesis inhibitor, as maintenance therapy following the completion of first line platinum based chemotherapy in women with advanced ovarian cancer	Beale	Transferred to LH 10/12/2013. 3 Pts remain in follow-up
Development of a Q-Stream Knowledge Translation Program on referral for Ovarian Cancer for Medical and Gynaecological Oncologists	Genetics	Closed – Data analysis
LH13.034: Symptom Benefit : QOL ANZGOG study in Platinum Refractory Ovarian cancer	Beale & Harrison	RECRUITMENT CLOSED 05/01/2015 Recruited: 13 Active: 1 Follow-up: 8 Deceased: 4